Crossmark

Phase I clinical study of NMB58, a novel positron emission tomography (PET)-myocardial perfusion imaging tracer, conducted to evaluate its safety and pharmacokinetics in Japanese healthy adult males

Crossref DOI link: https://doi.org/10.1007/s12149-021-01601-y

Published Online: 2021-03-01

Published Print: 2021-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kawano, Mirai

Tsuchiya, Junichi https://orcid.org/0000-0001-8392-2227
Bae, Hyeyeol

Kimura, Koichiro

Yokoyama, Kota

Takahashi, Marie

Honda, Makiko

Tominaga, Masato

Tateishi, Ukihide
License Information

Text and Data Mining valid from 2021-03-01

Version of Record valid from 2021-03-01
More Information

Article History

Received: 11 September 2020

Accepted: 15 February 2021

First Online: 1 March 2021

Compliance with ethical standards

:

: This study was sponsored by Nihon Medi-Physics Co., Ltd. (Tokyo, Japan). Assistance with manuscript preparation was provided by Pharma International (Tokyo, Japan) and funded by Nihon Medi-Physics Co., Ltd. Masato Tominaga is an employee of Nihon Medi-Physics Co., Ltd. The remaining authors have no conflict of interest to declare.

Document is current

Any future updates will be listed below